74
views
0
recommends
+1 Recommend
0 collections
    16
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study. Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events).

          Related collections

          Author and article information

          Journal
          Lancet Oncol
          The Lancet. Oncology
          Elsevier BV
          1474-5488
          1470-2045
          Oct 2012
          : 13
          : 10
          Affiliations
          [1 ] Institut Gustave Roussy, University of Paris Sud, Villejuif, France. karim.fizazi@igr.fr
          Article
          S1470-2045(12)70379-0
          10.1016/S1470-2045(12)70379-0
          22995653
          1e027c77-5bb4-46e2-8dc2-d4cabca4fa20
          Copyright © 2012 Elsevier Ltd. All rights reserved.
          History

          Comments

          Comment on this article